RE:RE:RE:RE:RE:RE:Antibody-Drug-Conjugate (ADC) company reports patient death Roche’s antibody drug conjugate (ADC) Kadcyla is up against Daiichi Sankyo’s Enhertu in metastatic breast cancer. And since Roche’s atezolizumab is being combined with pelarorep in the goblet study for pancreatic cancer, Roche would also be a suitable candidate for combining its immune checkpoint inibitor atezolizumab with pelareorep in the treatment of early metastatic breast cancer.